SCHEMBL1714568

SCHEMBL1714568

N#Cc1ccc(OCCCN2CCN(CCCOc3ccc(C#N)cn3)CC2)nc1

nearest known ligand 0.56

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 18/20 0.56
HRH1 P35367 13/20 0.54
HRH2 P25021 12/20 0.54
KCNJ1 P48048 1/20 0.45
KCNH2 Q12809 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1626866 0.94 HRH3 (0.51) HRH3HRH1HRH2
SCHEMBL18362733 0.87 MCHR1 (0.56) HRH3HRH1HRH2
SCHEMBL1461560 0.83 HRH2 (0.55) HRH3HRH1HRH2
SCHEMBL27381531 0.83 HRH1 (0.53) HRH3HRH1HRH2
SCHEMBL1715391 0.79 HRH3 (0.84) HRH3HRH1HRH2
SCHEMBL27291360 0.78 KDM4E (0.58)
SCHEMBL1400896 0.78 ALDH1A1 (0.41)
SCHEMBL12461904 0.78 KDM4E (0.41)
SCHEMBL1625928 0.77 HSD11B1 (0.44) HRH3HRH1HRH2
SCHEMBL26291417 0.77 TIPARP (0.54) HRH3HRH1HRH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1481966-B1 NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO LTD (JP) 2011-07-20 EP disclosed
US-7291617-B2 Arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-06 US disclosed
US-7291617-B2 Arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD. (JP) 2007-11-06 US disclosed
US-20050113424-A1 Novel arylamidine derivative or salt thereof TOYAMA CHEMICAL CO., LTD (JP) 2005-05-26 US disclosed
EP-1481966-A1 NOVEL ARYLAMIDINE DERIVATIVE OR SALT THEREOF TOYAMA CHEMICAL CO., LTD. (JP) 2004-12-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050113424-A1 Novel arylamidine derivative or salt thereof SLC7A1, NAT1, NACA HRH3 395/4885HRH1 386/4885HRH2 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.